4Cell Nutri-T Medium Serum-Free Medium
Excellent results and flexibility with xenofree serum-free medium for lymphocyte culture!
Cell-based immunotherapy is at the forefront of cancer treatment. The most common type of cell-based immunotherapy to date is T-cell therapy (with CAR-T and TIL being the mainstream). The cells used in immunotherapy are generally cultured in a medium supplemented with human serum. The use of serum introduces variability in the process due to individual differences among donors, leading to inconsistencies in cell growth and characteristics. By removing this serum and simplifying the process, regulatory risks are reduced, and the associated logistical burdens are alleviated. Nutri-T eliminates the need for serum by replacing its essential components with specific proteins, lipids, and other small molecules. <Product Overview> ■ Xeno-free ■ Serum-free, no serum supplementation required ■ Compliant with ISO13408 ■ For research use only ■ Developed using cells from actual cancer patients ■ Excellent results with PBMC, TIL, and CAR-T ■ Outstanding results at low initial seeding density
basic information
Benefits for Four Customers 〈Performance〉 ■ Excellent Fold Expansion ■ Superior survival rate and CD8+ expression rate ■ High transduction efficiency (%) for CAR-T applications 〈Flexibility〉 ■ Excellent results with healthy PBMCs, TILs, and CAR-T applications ■ Excellent results using cells derived from cancer patients ■ Outstanding results at low seeding concentrations 〈Safety〉 ■ Elimination of serum-related risks through serum-free conditions ■ Manufactured in compliance with ISO13408 guidelines ■ Robust shipping tests 〈Simplicity〉 ■ No need for serum raw materials, storage, or purchasing ■ Short lead times ensured by Nutri-T stock at our global facilities ■ Provision of our technical support and complementary products
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
Related Videos
catalog（9）
Download All Catalogs
News about this product（4）
-
Notice of Participation in the Luncheon Seminar at the 4th Annual Meeting of the Japanese Society for Antibody Research
"Next-Generation CHO Cell Line Development Service Integrating AI and Process Intensification - Innovation of Sartorius CLD Workflow" In biopharmaceutical development, establishing high-quality cell lines in a short period has become increasingly important. Sartorius's Cell Line Development (CLD) service has supported the approval of 7 antibody products and over 80 clinical projects to date. Seminar Points: ■ The latest workflow that selects optimal clones by AI analysis of nano-well images and fluorescence data immediately after single-cell cloning with CellCelector ■ A series of CLD processes that continue from Clone Evaluation, quality analysis, scale-up, to technology transfer to CDMO ■ Process Intensification strategies based on High Inoculation Fed-Batch and Perfusion culture ■ Media optimization service that can be used independently (supporting non-GMP prototypes to GMP manufacturing scale) Date and Time: December 3 (Wednesday) 12:20–13:20 Venue: Omiya Sonic City, Exhibition Hall 2
-
[End] Speaker at the Cell Culture Medium Symposium hosted by Shonan I-Park.
This event has concluded. We will be exhibiting and presenting at the Cell Culture Medium Symposium at Shonan, held at Shonan Ai Park on September 13, 2024 (Friday). At our booth, we will introduce Sartorius's wide range of media, raw materials, and services that meet the needs of cell culture. *You can view the program in the "Related Materials." [Event Overview] Date and Time: September 13, 2024 (Friday) 10:00 AM - 5:45 PM Location: Shonan Ai Park or online *Pre-registration required [Our Seminar] Title: Recombumin | Enabling safe and robust manufacturing across various modalities with recombinant human albumin Speaker: Shiori Akiyama (Sales Development Specialist - Cell Lines, Media, Various Tests) Seminar Time: 3:40 PM - 4:10 PM Overview: This seminar will focus on Recombumin, a recombinant human albumin that improves cell viability after cryopreservation and has an effect on suppressing the aggregation of cells and vectors.
-
[Sending recorded video] 4Cell Nutri-T Medium - Serum-free medium for the culture of CAR-T cells and TIL.
Participation in this webinar has ended. If you wish to view it, please contact us. We will send you the URL for the recorded video at a later date. Cellular immunotherapy has scientifically proven the efficacy of CAR-T cells in the treatment of blood cancers, and development is progressing globally. This has heightened interest in the scientific and medical communities and serves as a driving force to develop more effective and cost-efficient cellular immunotherapies. Therefore, the development of high-quality auxiliary materials such as culture media for cultivating these immune cells is crucial. To meet such needs, our company has developed the serum-free 4Cell Nutri-T Medium. Method of delivery: Webinar recorded broadcast (with Japanese subtitles, free of charge) *We sincerely apologize, but participation from email addresses other than those of your company or organization is not permitted. Thank you for your understanding.
-
[On-Demand Streaming Available] International Webinar "Accelerating CAR-T Process Development: Process Insights"
Registration for this webinar has ended. If you would like to access the on-demand version, please register through the details and application link provided. In this webinar, you will learn about leveling up the process development of T cells. <Main Content> - Promotion of media screening and identification and optimization of CPP (Critical Process Parameters) - Profiling of CAR-T cells and clustering of donors - Reduction of development time and COGs *Even if you cannot attend the live broadcast, those who register will receive a link to the on-demand archive. Starts on July 30 (Friday) at 00:00 (International time: July 29 (Thursday) 11:00 AM EDT | 8:00 AM PDT | 5 PM CEST) Related website https://bit.ly/2V9rh9u
Recommended products
Distributors
Sartorius Stedim, established in 2007 through the merger of the German company Sartorius, founded in 1870, and the French company Stedim, is a pioneer in "Single-Use Technology (SUT)." As a company capable of providing comprehensive technical support to the pharmaceutical and biotechnology industries, its cutting-edge technology is highly regarded worldwide in the fields of scientific instruments and biotechnology.